700 related articles for article (PubMed ID: 20399042)
21. Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study.
Prieto-Alhambra D; Javaid MK; Servitja S; Arden NK; Martinez-García M; Diez-Perez A; Albanell J; Tusquets I; Nogues X
Breast Cancer Res Treat; 2011 Feb; 125(3):869-78. PubMed ID: 20665105
[TBL] [Abstract][Full Text] [Related]
22. Serum 25-hydroxyvitamin D, parathyroid hormone, calcium intake, and bone mineral density in Spanish adults.
Olmos JM; Hernández JL; García-Velasco P; Martínez J; Llorca J; González-Macías J
Osteoporos Int; 2016 Jan; 27(1):105-13. PubMed ID: 26134682
[TBL] [Abstract][Full Text] [Related]
23. High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer.
Napoli N; Vattikuti S; Ma C; Rastelli A; Rayani A; Donepudi R; Asadfard M; Yarramaneni J; Ellis M; Armamento-Villareal R
Breast J; 2010; 16(6):609-16. PubMed ID: 21070438
[TBL] [Abstract][Full Text] [Related]
24. The impact of vitamin D status on changes in bone mineral density during treatment with bisphosphonates and after discontinuation following long-term use in post-menopausal osteoporosis.
Deane A; Constancio L; Fogelman I; Hampson G
BMC Musculoskelet Disord; 2007 Jan; 8():3. PubMed ID: 17214897
[TBL] [Abstract][Full Text] [Related]
25. Vitamin D and aromatase inhibitor-induced musculoskeletal symptoms (AIMSS): a phase II, double-blind, placebo-controlled, randomized trial.
Rastelli AL; Taylor ME; Gao F; Armamento-Villareal R; Jamalabadi-Majidi S; Napoli N; Ellis MJ
Breast Cancer Res Treat; 2011 Aug; 129(1):107-16. PubMed ID: 21691817
[TBL] [Abstract][Full Text] [Related]
26. Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole.
Singh S; Cuzick J; Mesher D; Richmond B; Howell A
Breast Cancer Res Treat; 2012 Apr; 132(2):625-9. PubMed ID: 22198469
[TBL] [Abstract][Full Text] [Related]
27. Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
Baatjes KJ; Kotze MJ; McCaul M; Conradie M
PLoS One; 2019; 14(4):e0214153. PubMed ID: 30939140
[TBL] [Abstract][Full Text] [Related]
28. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women.
Ishijima M; Sakamoto Y; Yamanaka M; Tokita A; Kitahara K; Kaneko H; Kurosawa H
Calcif Tissue Int; 2009 Nov; 85(5):398-404. PubMed ID: 19795092
[TBL] [Abstract][Full Text] [Related]
29. Effects of zoledronic acid on bone mineral density during aromatase inhibitor treatment of Korean postmenopausal breast cancer patients.
Lee SA; Hwang SH; Ahn SG; Lee HM; Jeong J; Lee HD
Breast Cancer Res Treat; 2011 Dec; 130(3):863-70. PubMed ID: 21861101
[TBL] [Abstract][Full Text] [Related]
30. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
Osteoporos Int; 2015 Jun; 26(6):1857-64. PubMed ID: 25792492
[TBL] [Abstract][Full Text] [Related]
31. [A prospective study of bone loss in early stage postmenopausal breast cancer treated with aromatase inhibitors].
Sun J; Wang Q; Wang L; Gui L; Li Q; Luo Y; Zhang S; Zhang P
Zhonghua Zhong Liu Za Zhi; 2020 May; 42(5):403-407. PubMed ID: 32482030
[No Abstract] [Full Text] [Related]
32. Vitamin D threshold to prevent aromatase inhibitor-related bone loss: the B-ABLE prospective cohort study.
Prieto-Alhambra D; Servitja S; Javaid MK; Garrigós L; Arden NK; Cooper C; Albanell J; Tusquets I; Diez-Perez A; Nogues X
Breast Cancer Res Treat; 2012 Jun; 133(3):1159-67. PubMed ID: 22434523
[TBL] [Abstract][Full Text] [Related]
33. Osteoporosis treatment and 10 years' oestrogen receptor+ breast cancer outcome in postmenopausal women treated with aromatase inhibitors.
Bouvard B; Chatelais J; Soulié P; Hoppé E; Saulnier P; Capitain O; Mege M; Mesgouez-Nebout N; Jadaud E; Abadie-Lacourtoisie S; Campone M; Legrand E
Eur J Cancer; 2018 Sep; 101():87-94. PubMed ID: 30036740
[TBL] [Abstract][Full Text] [Related]
34. The levels of bone turnover markers 25(OH)D and PTH and their relationship with bone mineral density in postmenopausal women in a suburban district in China.
Gao C; Qiao J; Li SS; Yu WJ; He JW; Fu WZ; Zhang ZL
Osteoporos Int; 2017 Jan; 28(1):211-218. PubMed ID: 27468899
[TBL] [Abstract][Full Text] [Related]
35. TBS and BMD at the end of AI-therapy: A prospective study of the B-ABLE cohort.
María RS; Marta PM; Sonia S; Natalia GG; Tamara M; Ignasi T; Maria MG; Jaime RM; Adolfo DP; Joan A; Xavier N
Bone; 2016 Nov; 92():1-8. PubMed ID: 27519968
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors for the efficacy of denosumab in postmenopausal Japanese women with non-metastatic breast cancer receiving adjuvant aromatase inhibitors: a combined analysis of two prospective clinical trials.
Nakatsukasa K; Koyama H; Ouchi Y; Sakaguchi K; Fujita Y; Matsuda T; Kato M; Konishi E; Taguchi T
J Bone Miner Metab; 2019 Sep; 37(5):864-870. PubMed ID: 30868270
[TBL] [Abstract][Full Text] [Related]
37. Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Van Poznak C; Hannon RA; Mackey JR; Campone M; Apffelstaedt JP; Clack G; Barlow D; Makris A; Eastell R
J Clin Oncol; 2010 Feb; 28(6):967-75. PubMed ID: 20065185
[TBL] [Abstract][Full Text] [Related]
38. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
[TBL] [Abstract][Full Text] [Related]
39. Morphometric vertebral fractures in breast cancer patients treated with adjuvant aromatase inhibitor therapy: A cross-sectional study.
Pedersini R; Monteverdi S; Mazziotti G; Amoroso V; Roca E; Maffezzoni F; Vassalli L; Rodella F; Formenti AM; Frara S; Maroldi R; Berruti A; Simoncini E; Giustina A
Bone; 2017 Apr; 97():147-152. PubMed ID: 28104509
[TBL] [Abstract][Full Text] [Related]
40. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
